American Society of Clinical Oncology

SHERPA: White

People

  1. Seidman
    Seidman
  2. Hudis
    Hudis
  3. Norton
    Norton
  4. D'Andrea-Carlino
    D'Andrea-Carlino
  5. Lake
    Lake
  6. Fornier
    Fornier
  7. Kris
    Kris
  8. Sklarin
    Sklarin
  9. Gucalp
    Gucalp
  10. Traina
    Traina

Groups

  1. Breast Medicine Service (84)
  2. Department of Medicine (84)
  3. Solid Tumor Oncology Division (84)
  4. Survivorship Research (51)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (35)
  6. Epidemiology and Biostatistics (27)
  7. Biostatistics Service (20)
  8. Population Sciences Research Program (18)
  9. Radiology, Department of (16)
  10. Psychiatry and Behavioral Sciences, Department of (12)
Search Within
  1. "Andrew Seidman"
Formats
  1. Meeting Abstract (51)
  2. Journal Article (32)
  3. Correspondence (1)
Groups
  1. Breast Medicine Service (84)
  2. Department of Medicine (84)
  3. Solid Tumor Oncology Division (84)
  4. Survivorship Research (51)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (35)
  6. Epidemiology and Biostatistics (27)

More Groups

People
  1. Andrew Seidman (84)
  2. Clifford Hudis (41)
  3. Larry Norton (31)
  4. Gabriella D'Andrea-Carlino (12)
  5. Diana Lake (10)
  6. Sujata Patil (10)

More People

Years
  1. 2023 (2)
  2. 2022 (2)
  3. 2021 (3)
  4. 2019 (2)
  5. 2018 (7)
  6. 2015 (5)

More Years

Publications
  1. Journal of Clinical Oncology (83)
  2. Journal of Oncology Practice (1)

Results (84)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase III trial of gemcitabine plus docetaxel (GD) compared to capecitabine plus docetaxel (CD) with planned crossover to the alternate single agent in metastatic breast cancer (MBC)
    Meeting Abstract

    Seidman, A. D.; Brufsky, A.; Ansari, R. H.; Rubinsak, J. R.; Stein, R. S.; Schwartzberg, L. S.; Stewart, J. F.; Zhao, L.; Gill, J.; Tai, D.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Dose-dense (DD) cyclophosphamide, methotrexate, and fluorouracil (CMF) at 14-day intervals: A pilot study of every 14- and 10-11-day dosing intervals for women with early-stage breast cancer
    Meeting Abstract

    Drullinsky, P.; Fornier, M. N.; Sugarman, S.; D'Andrea, G.; Troso-Sandoval, T.; Seidman, A. D.; Yuan, J.; Patil, S.; Norton, L.; Hudis, C.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Randomized phase II trial of nanoparticle albumin-bound paclitaxel in three dosing schedules with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC)
    Meeting Abstract

    Conlin, A. K.; Hudis, C. A.; Bach, A.; Moynahan, M.; Lake, D.; Forero-Torres, A.; Wright, G.; Hackney, M.; Clawson, A.; Seidman, A. D.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients
    Meeting Abstract

    Deng, G.; Smith-Jones, H. L.; Seidman, A. D.; Fornier, M.; D'Andrea, G.; Wesa, K.; Cunningham-Rundles, S.; Yeung, K. S.; Vickers, A.; Cassileth, B. R.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Phase II trial of patupilone in patients (pts) with breast cancer brain metastases (BCBM) progressing or recurring after whole brain radiation therapy (WBXRT)
    Meeting Abstract

    Conlin, A. K.; D'Andrea, G.; Hudis, C. A.; Robson, M. E.; Drullinsky, P.; Theodoulou, M.; Lis, E.; Kang, T. Y.; Peereboom, D. M.; Seidman, A. D.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Incidence and severity of sensory neuropathy (SN) with bevacizumab (B) added to dose-dense (dd) doxorubicin/cyclophosphamide (AC) followed by nanoparticle albumin-bound (nab) paclitaxel (P) in patients (pts) with early stage breast cancer (BC)
    Meeting Abstract

    Sierecki, M. R.; Rugo, H. S.; McArthur, H. L.; Traina, T. A.; Paulson, M.; Rourke, M.; Norton, L.; Seidman, A. D.; Hudis, C. A.; Dickler, M. N.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Clinical and pathologic correlates in breast cancer (BC) brain metastasis (BM): Tissue microarray (TMA) studies
    Meeting Abstract

    Johnson, M. L.; Nehhozina, T.; Conlin, A. K.; Hsu, M.; Patil, S.; Jhaveri, K.; Hudis, C. A.; Brogi, E.; Seidman, A. D.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Phase II study of weekly nanoparticle albumin bound (nab)paclitaxel with carboplatin and trastuzumab as 1st-line therapy for HER2-positive metastatic breast cancer (MBC)
    Meeting Abstract

    Seidman, A. D.; Conlin, A. K.; Bach, A.; Brufsky, A. M.; Saleh, M. N.; Lake, D.; Dickler, M. N.; D'Andrea, G.; Traina, T. A.; Hudis, C. A.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Phase II feasibility trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node-positive breast cancer: A trial of the Eastern Cooperative Oncology Group (E2104)
    Meeting Abstract

    Miller, K. D.; O'Neill, A.; Perez, E. A.; Seidman, A. D.; Sledge, G. W.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Preliminary safety results of dose-dense (dd) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2 overexpressed/amplified breast cancer (BCA)
    Meeting Abstract

    Dang, C. T.; Lin, N. U.; Lake, D.; Dickler, M. N.; Modi, S.; Seidman, A. D.; Steingart, R. M.; Norton, L.; Winer, E. P.; Hudis, C. A.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save